-
1
-
-
64949148074
-
-
Ministério da Saúde, Programa Nacional de Hepatites Virais, Brasília;
-
Ministério da Saúde - Programa Nacional de Hepatites Virais. Avaliação da Assistência às Hepatites Virais no Brasil. Brasília;2002:1-61.
-
(2002)
Avaliação da Assistência às Hepatites Virais no Brasil
, pp. 1-61
-
-
-
2
-
-
68349092468
-
-
Ministério da Saúde, Programa Nacional para a Prevenção e o Controle das Hepatites Virais. Disponível em:, 2007
-
Ministério da Saúde - Programa Nacional para a Prevenção e o Controle das Hepatites Virais. Disponível em: http://www.saude.gov.br/sps/areastecnicas/ hepatite.htm. 2007.
-
-
-
-
4
-
-
33746339209
-
A treatment algorithm for management of chronic hepatitis b vírus infection in the United States: Na update
-
Keeffe E.B., Dieterich D.T., Han S.H., et al A treatment algorithm for management of chronic hepatitis b vírus infection in the United States: na update. Clin Gastroenterol Hepatol 2006;4:936-62.
-
(2006)
Clin Gastroenterol Hepatol
, vol.4
, pp. 936-962
-
-
Keeffe, E.B.1
Dieterich, D.T.2
Han, S.H.3
-
5
-
-
33644827226
-
-
Hoofnagle J.H. Hepatitis B - Preventable and now treatable. N Engl J Med 2006;354:1074-6.
-
Hoofnagle J.H. Hepatitis B - Preventable and now treatable. N Engl J Med 2006;354:1074-6.
-
-
-
-
6
-
-
33846107571
-
Cross-study analysis of relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients
-
Dienstag J.L., Lee-Jen Wei, Dong Xu, Bruce Kreter. Cross-study analysis of relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients. Clin Drug Invest 2007; 27:35-49.
-
(2007)
Clin Drug Invest
, vol.27
, pp. 35-49
-
-
Dienstag, J.L.1
Jen Wei, L.2
Xu, D.3
Kreter, B.4
-
7
-
-
33644818518
-
A comparison of entecavir and lamivudine for AgHBe-positive chronic hepatitis B
-
Chang T.T., et al. A comparison of entecavir and lamivudine for AgHBe-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10.
-
(2006)
N Engl J Med
, vol.354
, pp. 1001-1010
-
-
Chang, T.T.1
-
8
-
-
33644822860
-
Entecavir versus lamivudine for patients with HBenegative chronic hepatitis B
-
Lai C.L., et al. Entecavir versus lamivudine for patients with HBenegative chronic hepatitis B. N Engl J Med 2006;354:1011-20.
-
(2006)
N Engl J Med
, vol.354
, pp. 1011-1020
-
-
Lai, C.L.1
-
9
-
-
29944436855
-
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
-
Chen C.J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295:65-73;
-
(2006)
JAMA
, vol.295
, pp. 65-73
-
-
Chen, C.J.1
-
10
-
-
33644858331
-
Predicting cirrhosis risk base don the level of circulating hepatitis B viral load
-
Iloeje U.H., et al. Predicting cirrhosis risk base don the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-86.
-
(2006)
Gastroenterology
, vol.130
, pp. 678-686
-
-
Iloeje, U.H.1
-
11
-
-
33644818518
-
A comparison of entecavir and lamivudine for AgHBe-positive chronic hepatitis B
-
Chang T.T., Gish R.G., Man R., et al. A comparison of entecavir and lamivudine for AgHBe-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10.
-
(2006)
N Engl J Med
, vol.354
, pp. 1001-1010
-
-
Chang, T.T.1
Gish, R.G.2
Man, R.3
-
12
-
-
33644822860
-
Entecavir versus lamivudine for patients with AgHBe-negative chronic hepatitis B
-
Lai C.L., Shouval D., Lok A.S., et al. Entecavir versus lamivudine for patients with AgHBe-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20.
-
(2006)
N Engl J Med
, vol.354
, pp. 1011-1020
-
-
Lai, C.L.1
Shouval, D.2
Lok, A.S.3
-
13
-
-
38149096996
-
Estimativas de custo da hepatite B crônica no sistema único de saúde brasileiro em 2005.
-
Castelo A., Pessoa M.G., Barreto T.C.B.B. Estimativas de custo da hepatite B crônica no sistema único de saúde brasileiro em 2005. Rev Assoc Med Bras 2007;53:486-91.
-
(2007)
Rev Assoc Med Bras
, vol.53
, pp. 486-491
-
-
Castelo, A.1
Pessoa, M.G.2
Barreto, T.C.B.B.3
-
14
-
-
68349098324
-
-
Instituto Brasileiro de Geografia e Estatística IBGE, Disponível em:, 2008
-
Instituto Brasileiro de Geografia e Estatística (IBGE). Disponível em: www.ibge.gov.br. 2008.
-
-
-
-
15
-
-
0028137860
-
DEALE-ing and discounting: A simple way to compute the accrued costs of preventive strategies
-
Durand-Zaleski I., Zaleski S. DEALE-ing and discounting: a simple way to compute the accrued costs of preventive strategies. Med Decis Making 1994;14:98-03.
-
(1994)
Med Decis Making
, vol.14
, pp. 98-03
-
-
Durand-Zaleski, I.1
Zaleski, S.2
-
16
-
-
0035128185
-
Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: A cost effectiveness analysis
-
Bolondi L., Sofia S., Siringo S., et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48:251-9.
-
(2001)
Gut
, vol.48
, pp. 251-259
-
-
Bolondi, L.1
Sofia, S.2
Siringo, S.3
-
17
-
-
0036840812
-
Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: A cohort study of 297 patients
-
Fattovich G., Pantalena M., Zagni I., et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002;97:2886-95.
-
(2002)
Am J Gastroenterol
, vol.97
, pp. 2886-2895
-
-
Fattovich, G.1
Pantalena, M.2
Zagni, I.3
-
18
-
-
68349107701
-
The impact of chronic hepatitis B on quality of life: A multinational study of utilities from infected and uninfected persons
-
December
-
Levy A.R., Kowdley K.V., Iloeje U., et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value in Health 2007 (December).
-
(2007)
Value in Health
-
-
Levy, A.R.1
Kowdley, K.V.2
Iloeje, U.3
-
19
-
-
35549005997
-
Cost-effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B
-
Veenstra D.L., Sullivan S.D., Clarke L., et al. Cost-effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2007; 25:963-77.
-
(2007)
Pharmacoeconomics
, vol.25
, pp. 963-977
-
-
Veenstra, D.L.1
Sullivan, S.D.2
Clarke, L.3
-
20
-
-
33748337737
-
Treatment alternatives for hepatitis B cirrhosis: A cost-effectiveness analysis
-
Kanwal F., Farid M., Martin P., et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol 2006;101:2076-89.
-
(2006)
Am J Gastroenterol
, vol.101
, pp. 2076-2089
-
-
Kanwal, F.1
Farid, M.2
Martin, P.3
-
21
-
-
40149083254
-
Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAgpositive chronic hepatitis B patients
-
Yuan Y., Iloeje U.H., Hay J., Saab S. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAgpositive chronic hepatitis B patients. J Manag Care Pharm 2008;14:21-33.
-
(2008)
J Manag Care Pharm
, vol.14
, pp. 21-33
-
-
Yuan, Y.1
Iloeje, U.H.2
Hay, J.3
Saab, S.4
|